Article Text

Download PDFPDF
Letter
Epinephrine use in COVID-19: friend or foe?
  1. Pan Luo,
  2. Dong Liu,
  3. Juan Li
  1. Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
  1. Correspondence to Professor Juan Li, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; lijuan{at}tjh.tjmu.edu.cn; Professor Dong Liu, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; l_d2069{at}163.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now overwhelming, spreading throughout the world, and has been declared a global pandemic by the WHO. So far, more than 4 million confirmed cases have been reported by WHO worldwide, including more than 290,000 deaths. And the treatment for the critically ill patients of COVID-19 remains a challenge.

The first report of pathological characteristics of the patient who died from severe infection with SARS-CoV-2 demonstrated an increased concentration of highly proinflammatory cytokines.1 Actually, the cytokine storm mediated by overproduction of proinflammatory cytokines has been observed in a large population of critically ill patients with COVID-19.2 Cytokine storms can result in cardiovascular collapse, multiple organ dysfunction, cardiac arrest, and death. Epinephrine, a vasoactive agent, has been routinely employed to the critical situation such as cardiac arrest. However, it remains uncertain whether epinephrine can also benefit the cardiac arrest following cytokine storms occurred in …

View Full Text

Footnotes

  • Contributors PL wrote the paper. JL and DL revised it.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.